FLT3LG and neoplasm: We believe this is because Alb-Flt3L–expanded DCs can take up tumor antigen in the tumor microenvironment that is released by radiation or chemotherapy, process and cross-present these antigens, and expand preexisting pools of neoantigen-specific T cells in the mice, which then mediate tumor control.